Emerging Company Profile

Lumen growing lean, green biologics with $16M series B and Gates funding

Having wrangled spirulina into making oral biologics, Lumen aims for low cost and high volume

Having wrangled spirulina into making oral biologics, Lumen aims for low cost, high volume indications in the Western and developing worlds.

Having turned photosynthetic bacteria into protein production machines, Lumen believes it has cracked the code to making cheap, oral biologics for widespread diseases in the Western and developing worlds.

The company’s $16 million series